SU-DIPG-13 NTCC®弥漫型内因性脑桥神经胶细胞瘤细胞株cell line-BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

• Stem-like properties

  ALDH+ SU-DIPG XIII cells have greater proliferation and neurosphere size than ALDH- cells, suggesting the presence of cancer stem cells in DIPG tumors.
• Synergistic activity

  The combination of ONC201 and HDAC inhibitors, such as panobinostat or romidepsin, has synergistic activity against SU-DIPG-13 cells.
• Transcriptional vulnerabilities

  DIPG cells are vulnerable to transcriptional disruption through bromodomain inhibition or CDK7 blockade.
• CDK7 inhibition

  THZ1, a CDK7 inhibitor, can reduce the growth of DIPG xenografts in vivo and increase median survival in mice.

DIPG is the leading cause of brain tumor-related death in children. The standard treatment is radiation alone, as complete resection is not possible and conventional chemotherapy is ineffective.

Cell pictures: